# XACDURO (xacduro) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/xacduro

> The FDA approved XACDURO (xacduro), sponsored by Innoviva, Inc. (INVA), on May 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is XACDURO (xacduro) FDA approved?

Yes. The FDA approved XACDURO (xacduro), sponsored by Innoviva, Inc. (INVA), on May 2023. SEC Form 10-Q: "Following the FDA approval of XACDURO® in May 2023, we started amortizing $68.7 million of the then in-process research and development as a marketed product, as well as the collaboration agreement, over their estimated useful lives." [Calendar and source filings](https://sec-api.dev/pdufa/xacduro)

Source: SEC Form 10-Q, accession 0001193125-26-447384, https://www.sec.gov/Archives/edgar/data/1080014/000119312526447384/inva-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/pdufa/xacduro#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | XACDURO (xacduro) |
| Codes |  |
| Sponsor | Innoviva, Inc. (INVA) https://sec-api.dev/companies/inva/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### May 2023: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-02-26, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001193125-26-447384): "Following the FDA approval of XACDURO® in May 2023, we started amortizing $68.7 million of the then in-process research and development as a marketed product, as well as the collaboration agreement, over their estimated useful lives." https://www.sec.gov/Archives/edgar/data/1080014/000119312526447384/inva-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-335235): "Following the FDA approval of XACDURO® in May 2023, we started amortizing $68.7 million of the then in-process research and development as a marketed product, as well as the collaboration agreement, over their estimated useful lives." https://www.sec.gov/Archives/edgar/data/1080014/000119312526335235/inva-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-209110): "Following the FDA approval of XACDURO® in May 2023, we started amortizing $68.7 million of the then in-process research and development as a marketed product, as well as the collaboration agreement, over their estimated useful lives." https://www.sec.gov/Archives/edgar/data/1080014/000119312526209110/inva-20260331.htm
- SEC Form 10-K (accession 0001193125-26-071776): "Following the FDA approval of XACDURO® in May 2023, we started amortizing $68.7 million of the then in-process research and development as a marketed product, as well as the collaboration agreement, over their estimated useful lives." https://www.sec.gov/Archives/edgar/data/1080014/000119312526071776/inva-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-267040): "Following the FDA approval of XACDURO® in May 2023, we started amortizing $68.7 million of the then in-process research and development as a marketed product, as well as the collaboration agreement, over their estimated useful lives." https://www.sec.gov/Archives/edgar/data/1080014/000119312525267040/inva-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-104126): "Following the FDA approval of XACDURO® in May 2023, we started amortizing $68.7 million of the then in-process research and development as a marketed product, as well as the collaboration agreement, over their estimated useful lives." https://www.sec.gov/Archives/edgar/data/1080014/000095017025104126/inva-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-065765): "Following the FDA approval of XACDURO® in May 2023, we started amortizing $68.7 million of the then in-process research and development as a marketed product, as well as the collaboration agreement, over their estimated useful lives." https://www.sec.gov/Archives/edgar/data/1080014/000095017025065765/inva-20250331.htm
- SEC Form 10-K (accession 0000950170-25-027864): "Following the FDA approval of XACDURO® in May 2023, we started amortizing $68.7 million of the then in-process research and development as a marketed product, as well as the collaboration agreement, over their estimated useful lives." https://www.sec.gov/Archives/edgar/data/1080014/000095017025027864/inva-20241231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/xacduro.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "XACDURO (xacduro) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/xacduro

```bibtex
@misc{secapidev_pdufa_xacduro_20261116,
  title        = {XACDURO (xacduro) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/xacduro}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_xacduro_20261116","title":"XACDURO (xacduro) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/xacduro","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
